LENZ
LENZ Therapeutics Inc
NASDAQ: LENZ · HEALTHCARE · BIOTECHNOLOGY
$8.98
-0.77% today
Updated 2026-04-30
Market cap
$306.02M
P/E ratio
—
P/S ratio
16.03x
EPS (TTM)
$-2.85
Dividend yield
—
52W range
$8 – $50
Volume
0.9M
LENZ Therapeutics Inc (LENZ) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $15.00M | $0.00 | $0.00 | $19.09M |
| Revenue growth (YoY) | — | — | — | — | -100.0% | — | — |
| Cost of revenue | — | $121000.00 | $734000.00 | $8.35M | $2.41M | $58000.00 | $418000.00 |
| Gross profit | — | $-121000.00 | $-734000.00 | $15.00M | $-2.41M | $-58000.00 | $18.67M |
| Gross margin | — | — | — | 100.0% | — | — | 97.8% |
| R&D | — | $9.12M | $37.93M | $21.13M | $59.50M | $29.80M | $18.67M |
| SG&A | — | — | $2.47M | $4.36M | $12.93M | $28.81M | $91.14M |
| Operating income | $-29000.00 | $-13.50M | $-60.44M | $-10.48M | $-72.43M | $-58.61M | $-91.14M |
| Operating margin | — | — | — | -69.9% | — | — | -477.5% |
| EBITDA | $142860.00 | $-68.21M | $-70.03M | $-10.47M | $-72.41M | $-49.71M | $-91.14M |
| EBITDA margin | — | — | — | -69.8% | — | — | -477.5% |
| EBIT | $-29000.00 | $-68.33M | $-70.76M | $-10.48M | $-72.43M | $-49.77M | $-91.42M |
| Interest expense | $80000.00 | $40000.00 | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-109000.00 | $-68.37M | $-70.76M | $-10.81M | $-69.97M | $-49.77M | $-82.13M |
| Net income growth (YoY) | — | -62627.5% | -3.5% | +84.7% | -547.2% | +28.9% | -65.0% |
| Profit margin | — | — | — | -72.1% | — | — | -430.3% |